Organization
Barts Health NHS Trust and the Royal Free NHS Foundation Trust
10 abstracts
Abstract
Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma: 5-year analysis of KEYNOTE-426.Org: Vanderbilt-Ingram Cancer Center, Russian Scientific Center of Roentgenoradiology, Central Clinical Hospital With Outpatient Clinic, Centre Hospitalier de l’Université de Montréal, Hospital de Clínicas de Porto Alegre,
Abstract
Biomarker analysis of the phase 3 KEYNOTE-426 study of pembrolizumab (P) plus axitinib (A) versus sunitinib (S) for advanced renal cell carcinoma (RCC).Org: Merck & Co., Inc., Rahway, NJ, MSD UK, London, United Kingdom, Barts Health NHS Trust and the Royal Free NHS Foundation Trust, Barts Cancer Institute, London, United Kingdom, Vanderbilt-Ingram Cancer Center,
Abstract
Real world experience of trastuzumab deruxtecan for the treatment of metastatic breast cancer in the UK.Org: Royal Free London NHS Foundation Trust, The Christie NHS Foundation Trust, Barts Health NHS Trust and the Royal Free NHS Foundation Trust, Guys' and St Thomas' NHS Trust, Belfast Health and Social Care Trust,
Abstract
Belzutifan plus lenvatinib for patients (pts) with advanced clear cell renal cell carcinoma (ccRCC) after progression on a PD-1/L1 and VEGF inhibitor: Preliminary results of arm B5 of the phase 1/2 KEYMAKER-U03B study.Org: Gustave Roussy Département d'Organisation du Parcours Patient, Vanderbilt University Medical Center, Jewish General Hospital Stroll Cancer Prevention Centre, Queensland Health, Ramón y Cajal University Hospital,
Abstract
Neoadjuvant immunotherapy with ipilimumab plus nivolumab and radiologically and pathologically quantifiable responses through modulation of the tumour microenvironment in resectable hepatocellular carcinoma.Org: Imperial College, Imperial College London, Imperial College, St Mary's Campus, Imperial College Healthcare NHS Trust, Barts and The London HPB Centre,
Abstract
Effect of a digital biopsychometric risk profile of patients with cancer on the delivery of risk-stratified personalised prehabilitation.Org: Imperial College, Imperial College Healthcare NHS Trust, Barts Health NHS Trust and the Royal Free NHS Foundation Trust, Barking, Havering and Redbridge NHS Trust, Onkohealth,
Abstract
Immune-related adverse events after ≥12 months of starting immune checkpoint inhibitors.Org: Barts Cancer Institute, Barts Cancer Centre, Queen Mary University of London, Barts Health NHS Trust and the Royal Free NHS Foundation Trust, St Bart's Hospital,
Abstract
Outcomes and safety of subsequent treatments after immune- and anti-VEGF therapy in patients with metastatic clear-cell renal cell carcinoma: Outcomes from a tertiary referral hospital.Org: Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barts Cancer Institute, Barts Health NHS Trust and the Royal Free NHS Foundation Trust,
Abstract
A PILOT STUDY TO PREPARE FOR AN INVESTIGATION OF CORTICOSPINAL EXCITABILITY IN PEOPLE WITH JOINT HYPERMOBILITY SYNDROME Org: Barts Health NHS Trust and the Royal Free NHS Foundation Trust, Physiotherapy, Imperial College London Healthcare NHS Trust, Department of Surgery and Cancer, Imperial College, London, London, United Kingdom,
Abstract
A SIMPLE CLINICAL SCORING TOOL CAN BE USED TO IMPROVE PATIENT SELECTION FOR ULTRASOUND IN DIAGNOSING EARLY INFLAMMATORY ARTHRITISOrg: Barts Health NHS Trust and the Royal Free NHS Foundation Trust, Rheumatology, London Regional Cancer Center,